Who is sponsoring NCT00994253?

NCT00994253 is sponsored by Corewell Health East.

What condition does NCT00994253 study?

NCT00994253 studies Hypertension, Diabetes Type 2.

What drugs are being tested in NCT00994253?

Interventions: Aliskiren, Hydrochlorothiazide.

What is the status of NCT00994253?

NCT00994253 is currently WITHDRAWN.

Last reviewed 2017-09-27 · How we verify

A Prospective, Randomized, Open-label Clinical Trial to Evaluate the Effect of Tekturna (Aliskiren), Angiotensin Inhibitors, Diuretics, and Calcium Channel Blockers on Coronary Flow Reserve in Patients With Type II Diabetes and Hypertension

NCT00994253 Phase 4 WITHDRAWN

The purpose of this study is to assess the effect of Tekturna (aliskiren), in combination with an ACE and calcium channel blocker in hypertensive patients diagnosed with Type II diabetes.

Details

Lead sponsor	Corewell Health East
Phase	Phase 4
Status	WITHDRAWN
Start date	2009-08
Completion	2012-12

Conditions

Hypertension
Diabetes Type 2

Interventions

Aliskiren
Hydrochlorothiazide

Primary outcomes

The primary objective is to assess the effect of a multimodal drug therapy regimen including the renin inhibitor Tekturna (aliskiren), an ACE inhibitor, and a calcium channel blocker on coronary flow reserve (CFR) in hypertensive Type II diabetics. — 6 months
CFR will be assessed by a PET-based imaging technique.

Countries

United States